Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
- Author
- GRINSZTEJN, Beatriz1 ; DE CASTRO, Nathalie2 ; VORSATZ, Carla1 ; FAGARD, Catherine4 ; SANTINI-OLIVEIRA, Marilia1 ; PATEY, Olivier11 ; DELAUGERRE, Constance3 ; CHENE, Geneviève12 4 ; MOLINA, Jean-Michel2 ; ARNOLD, Vincent4 ; VELOSO, Valdiléa G1 ; MORGADO, Mariza5 ; PILOTTO, José Henrique6 ; BRITES, Carlos7 ; MADRUGA, José Valdez8 ; BARCELLOS, Nêmora Tregnago9 ; SANTOS, Breno Riegel10
[1] STD/AIDS Clinical Research, Laboratory-Evandro Chagas, Clinical Research Institute-Fiocruz, Brazil
[2] University of Paris Diderot Paris 7, Sorbonne Paris Cité, INSERM U941, Department of Infectious Diseases, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, France
[3] Department of Virology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, France
[4] INSERM U897, University of Bordeaux, ISPED, Epidemiologie- Biostatistique, Bordeaux, France
[5] Laboratory of AlDS and Molecular Immunology, Oswaldo Cruz Institute-Fiocruz, Rio de Janeiro, Brazil
[6] Departamento de DST/AIDS, Hospital Geral de Nova Iguaçu, Rio de Janeiro, Brazil
[7] Laboratório de Pesquisa em Doenças Infecciosas, Hospital Universitário Prof Edgar Santos, Bahia, Brazil
[8] Centro de Referência e Treinamento DST/AIDS, São Paulo, Brazil
[9] Hospital Sanatório Partenon, Health State Secretariat/RS, Brazil
[10] Serviço de Infectologia, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
[11] Department of Internal and Tropical Medicine, Villeneuve St George, France
[12] CHU de Bordeaux, Pôle de Santé Publique, Service d'information médicale, Bordeaux, France
ANRS 12 180 Reflate TB study group, France - Source
Lancet. Infectious diseases (print). 2014, Vol 14, Num 6, pp 459-467, 9 p ; ref : 23 ref
- ISSN
- 1473-3099
- Scientific domain
- General medicine general surgery; Microbiology, infectious diseases
- Publisher
- Lancet Publishing Group, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antirétroviral Antiviral Etude comparative Homme Infection mixte Raltégravir SIDA Traitement Tuberculose Virus immunodéficience humaine Inhibiteur de transfert de brins Bactériose Immunodéficit Immunopathologie Infection Inhibiteur de l'intégrase Lentivirus Mycobactériose Retroviridae Virose Virus
- Keyword (en)
- Antiretroviral agent Antiviral Comparative study Human Mixed infection Raltegravir AIDS Treatment Tuberculosis Human immunodeficiency virus Bacteriosis Immune deficiency Immunopathology Infection Integrase inhibitor Lentivirus Mycobacterial infection Retroviridae Viral disease Virus
- Keyword (es)
- Antiretroviral Antiviral Estudio comparativo Hombre Infección mixta Raltegravir SIDA Tratamiento Tuberculosis Human immunodeficiency virus Bacteriosis Inmunodeficiencia Inmunopatología Infección Inhibidor integrase Lentivirus Micobacteriosis Retroviridae Virosis Virus
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents / 002B02S05 Antiviral agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05B Bacterial diseases / 002B05B02 Human bacterial diseases / 002B05B02O Tuberculosis and atypical mycobacterial infections
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Discipline
- Infectious pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 28495120
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S1473-3099(14)70711-X 
https://dx.doi.org/10.1016/S1473-3099(14)70711-X
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70711-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"459\";s:8:\"\u0000*\u0000epage\";s:3:\"467\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"GRINSZTEJN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Beatriz\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DE CASTRO, Nathalie\";i:1;s:14:\"VORSATZ, Carla\";i:2;s:17:\"FAGARD, Catherine\";i:3;s:25:\"SANTINI-OLIVEIRA, Marilia\";i:4;s:14:\"PATEY, Olivier\";i:5;s:21:\"DELAUGERRE, Constance\";i:6;s:17:\"CHENE, Genevi\u00e8ve\";i:7;s:19:\"MOLINA, Jean-Michel\";i:8;s:15:\"ARNOLD, Vincent\";i:9;s:19:\"VELOSO, Valdil\u00e9a G\";i:10;s:15:\"MORGADO, Mariza\";i:11;s:23:\"PILOTTO, Jos\u00e9 Henrique\";i:12;s:14:\"BRITES, Carlos\";i:13;s:21:\"MADRUGA, Jos\u00e9 Valdez\";i:14;s:27:\"BARCELLOS, N\u00eamora Tregnago\";i:15;s:20:\"SANTOS, Breno Riegel\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70711-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"459\";s:8:\"\u0000*\u0000epage\";s:3:\"467\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"GRINSZTEJN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Beatriz\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DE CASTRO, Nathalie\";i:1;s:14:\"VORSATZ, Carla\";i:2;s:17:\"FAGARD, Catherine\";i:3;s:25:\"SANTINI-OLIVEIRA, Marilia\";i:4;s:14:\"PATEY, Olivier\";i:5;s:21:\"DELAUGERRE, Constance\";i:6;s:17:\"CHENE, Genevi\u00e8ve\";i:7;s:19:\"MOLINA, Jean-Michel\";i:8;s:15:\"ARNOLD, Vincent\";i:9;s:19:\"VELOSO, Valdil\u00e9a G\";i:10;s:15:\"MORGADO, Mariza\";i:11;s:23:\"PILOTTO, Jos\u00e9 Henrique\";i:12;s:14:\"BRITES, Carlos\";i:13;s:21:\"MADRUGA, Jos\u00e9 Valdez\";i:14;s:27:\"BARCELLOS, N\u00eamora Tregnago\";i:15;s:20:\"SANTOS, Breno Riegel\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70711-X\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70711-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"459\";s:8:\"\u0000*\u0000epage\";s:3:\"467\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"GRINSZTEJN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Beatriz\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DE CASTRO, Nathalie\";i:1;s:14:\"VORSATZ, Carla\";i:2;s:17:\"FAGARD, Catherine\";i:3;s:25:\"SANTINI-OLIVEIRA, Marilia\";i:4;s:14:\"PATEY, Olivier\";i:5;s:21:\"DELAUGERRE, Constance\";i:6;s:17:\"CHENE, Genevi\u00e8ve\";i:7;s:19:\"MOLINA, Jean-Michel\";i:8;s:15:\"ARNOLD, Vincent\";i:9;s:19:\"VELOSO, Valdil\u00e9a G\";i:10;s:15:\"MORGADO, Mariza\";i:11;s:23:\"PILOTTO, Jos\u00e9 Henrique\";i:12;s:14:\"BRITES, Carlos\";i:13;s:21:\"MADRUGA, Jos\u00e9 Valdez\";i:14;s:27:\"BARCELLOS, N\u00eamora Tregnago\";i:15;s:20:\"SANTOS, Breno Riegel\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70711-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"459\";s:8:\"\u0000*\u0000epage\";s:3:\"467\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"GRINSZTEJN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Beatriz\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DE CASTRO, Nathalie\";i:1;s:14:\"VORSATZ, Carla\";i:2;s:17:\"FAGARD, Catherine\";i:3;s:25:\"SANTINI-OLIVEIRA, Marilia\";i:4;s:14:\"PATEY, Olivier\";i:5;s:21:\"DELAUGERRE, Constance\";i:6;s:17:\"CHENE, Genevi\u00e8ve\";i:7;s:19:\"MOLINA, Jean-Michel\";i:8;s:15:\"ARNOLD, Vincent\";i:9;s:19:\"VELOSO, Valdil\u00e9a G\";i:10;s:15:\"MORGADO, Mariza\";i:11;s:23:\"PILOTTO, Jos\u00e9 Henrique\";i:12;s:14:\"BRITES, Carlos\";i:13;s:21:\"MADRUGA, Jos\u00e9 Valdez\";i:14;s:27:\"BARCELLOS, N\u00eamora Tregnago\";i:15;s:20:\"SANTOS, Breno Riegel\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70711-X\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"459\";s:8:\"\u0000*\u0000epage\";s:3:\"467\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"GRINSZTEJN\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Beatriz\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:16:{i:0;s:19:\"DE CASTRO, Nathalie\";i:1;s:14:\"VORSATZ, Carla\";i:2;s:17:\"FAGARD, Catherine\";i:3;s:25:\"SANTINI-OLIVEIRA, Marilia\";i:4;s:14:\"PATEY, Olivier\";i:5;s:21:\"DELAUGERRE, Constance\";i:6;s:17:\"CHENE, Genevi\u00e8ve\";i:7;s:19:\"MOLINA, Jean-Michel\";i:8;s:15:\"ARNOLD, Vincent\";i:9;s:19:\"VELOSO, Valdil\u00e9a G\";i:10;s:15:\"MORGADO, Mariza\";i:11;s:23:\"PILOTTO, Jos\u00e9 Henrique\";i:12;s:14:\"BRITES, Carlos\";i:13;s:21:\"MADRUGA, Jos\u00e9 Valdez\";i:14;s:27:\"BARCELLOS, N\u00eamora Tregnago\";i:15;s:20:\"SANTOS, Breno Riegel\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:175:\"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
